OPALEYE MANAGEMENT Overview
Opaleye Management Inc. is a hedge fund that manages 225.1 MM dollars in regulatory AUM and has 3 employees, of which 3 perform investment advisory functions.
The manager's has disclosed holdings from 12/31/13 to 06/31/18. The fund's latest filing disclosed 386MM in positions, representing 172% of the manager's regulatory AUM.
The manager's has disclosed holdings from 12/31/13 to 06/31/18. The fund's latest filing disclosed 386MM in positions, representing 172% of the manager's regulatory AUM.
OPALEYE MANAGEMENT StockAlpha
| Top 25% |
3yr StockAlpha
Register for more...
Fundamental & Technical Factor Exposure
OPALEYE MANAGEMENT Since Last Filing Return Details
| Ticker | Size | Sector | Stock Move | StockAlpha Attribution | Days to Liquidate | Trade Crowdedness | ||
|---|---|---|---|---|---|---|---|---|
| AXGN | 18.73% | Health | -32.88% | -7.66% | 3 | 4% | ||
| LOXO | 7.86% | Health | -9.4% | -1.68% | 0 | 4% | ||
|
Get the Full Report |
||||||||
FEATURED IN
OPALEYE MANAGEMENT Founders and Key Employees
| Name | Title | In Position Since |
|---|
| James A. Silverman | President/Chief Compliance Officer | February-1996 |
OPALEYE MANAGEMENT Brokers, Custodians, Auditors and Administrators
| Type | Company |
|---|
| Administrator | Pro |
| Auditor | Pro |
| Custodian | Pro |
| Custodian | Pro |
| Prime Broker | Pro |
OPALEYE MANAGEMENT Investment Strategy
Methods of Analysis, Investment Strategies and Risk of Loss
We employ a research process that involves analyzing company fundamentals. Such as asset valuations, quality of management, likely catalysis and/ or innovative products and the competition.
Opaleye's strategy for managing the Fund is to actively invest, both long and short, in equity securities of biotechnology, specialty pharmaceutical and med-device companies. In pursuing this strategy, the Fund will focus its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The Fund will also seek to actively invest in stock and derivative transactions to profit from “binary” events, such as clinical data milestones or a U.S. Food and Drug Administration (“FDA...
Get the Full Report
We employ a research process that involves analyzing company fundamentals. Such as asset valuations, quality of management, likely catalysis and/ or innovative products and the competition.
Opaleye's strategy for managing the Fund is to actively invest, both long and short, in equity securities of biotechnology, specialty pharmaceutical and med-device companies. In pursuing this strategy, the Fund will focus its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The Fund will also seek to actively invest in stock and derivative transactions to profit from “binary” events, such as clinical data milestones or a U.S. Food and Drug Administration (“FDA...
Get the Full Report
OPALEYE MANAGEMENT Portfolio Concentration
OPALEYE MANAGEMENT Location
OPALEYE MANAGEMENT Contact Information
Phone Number: 617-229-5085
Fax Number: 617-812-0515
Website: null
Fax Number: 617-812-0515
Website: null
READ RECENT SYMMETRIC REPORTS
Disclaimer
The information contained herein: (1) is proprietary to Symmetric and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Symmetric nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance and skill metrics are no guarantee of future results. "Symmetric," "Symmetric.io" and the Symmetric logo are marks of Symmetric, Inc. Read our privacy policy here. Read our terms of use here
